JP2020531539A5 - - Google Patents

Download PDF

Info

Publication number
JP2020531539A5
JP2020531539A5 JP2020511450A JP2020511450A JP2020531539A5 JP 2020531539 A5 JP2020531539 A5 JP 2020531539A5 JP 2020511450 A JP2020511450 A JP 2020511450A JP 2020511450 A JP2020511450 A JP 2020511450A JP 2020531539 A5 JP2020531539 A5 JP 2020531539A5
Authority
JP
Japan
Prior art keywords
canakinumab
patient
use according
recurrent
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020511450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531539A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/056465 external-priority patent/WO2019038737A1/en
Publication of JP2020531539A publication Critical patent/JP2020531539A/ja
Publication of JP2020531539A5 publication Critical patent/JP2020531539A5/ja
Withdrawn legal-status Critical Current

Links

JP2020511450A 2017-08-25 2018-08-24 カナキヌマブの使用 Withdrawn JP2020531539A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762549971P 2017-08-25 2017-08-25
US62/549,971 2017-08-25
US201762584380P 2017-11-10 2017-11-10
US62/584,380 2017-11-10
PCT/IB2018/056465 WO2019038737A1 (en) 2017-08-25 2018-08-24 USE OF CANAKINUMAB

Publications (2)

Publication Number Publication Date
JP2020531539A JP2020531539A (ja) 2020-11-05
JP2020531539A5 true JP2020531539A5 (enExample) 2021-09-30

Family

ID=63643018

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020511441A Withdrawn JP2020531537A (ja) 2017-08-25 2018-08-24 カナキヌマブの使用
JP2020511450A Withdrawn JP2020531539A (ja) 2017-08-25 2018-08-24 カナキヌマブの使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020511441A Withdrawn JP2020531537A (ja) 2017-08-25 2018-08-24 カナキヌマブの使用

Country Status (5)

Country Link
US (3) US20200239564A1 (enExample)
EP (2) EP3710476A1 (enExample)
JP (2) JP2020531537A (enExample)
TW (2) TW201919695A (enExample)
WO (2) WO2019038740A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112040953A (zh) * 2018-03-09 2020-12-04 布赖汉姆妇女医院 用于心血管疾病的组合治疗
WO2022023907A1 (en) 2020-07-31 2022-02-03 Novartis Ag Methods of selecting and treating patients at elevated risk of major adverse cardiac events
CN113491820A (zh) * 2021-07-30 2021-10-12 复旦大学附属中山医院 涂层Canakinumab的药物球囊的制备及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
BR112014007253A2 (pt) 2011-09-30 2017-03-28 Novartis Ag uso de anticorpos que se ligam a il-1beta

Similar Documents

Publication Publication Date Title
Marsico et al. NSAIDs and cardiovascular risk
Levien Advances in the treatment of Raynaud’s phenomenon
JP2019514925A5 (enExample)
JP2018193377A5 (enExample)
HRP20221150T1 (hr) Semaglutid u kardiovaskularnim stanjima
JP2020531539A5 (enExample)
JP2018111728A5 (enExample)
JP2019507797A5 (enExample)
Iacoviello et al. Recent advances in pharmacological treatment of heart failure
JP2017503820A5 (enExample)
HRP20220058T1 (hr) Sastavi i metode za smanjenje velikih neželjenih kardiovaskularnih događaja
Siak et al. The use of colchicine in cardiovascular diseases: a systematic review
HRP20230935T1 (hr) Postupci za liječenje i profilaksu hiv-a i aids-a
JP2018530578A5 (enExample)
Soleimani et al. The effect of intravenous N-acetylcysteine on prevention of atrial fibrillation after coronary artery bypass graft surgery: a double-blind, randomised, placebo-controlled trial
JP2020533302A5 (enExample)
MX2018000084A (es) Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina.
Chen et al. Teaching an old dog new tricks: colchicine in cardiovascular medicine
JP2020531537A5 (enExample)
JP2017519762A5 (enExample)
JP2019533715A5 (enExample)
JP2016512247A5 (enExample)
RU2018104691A (ru) Композиции с модифицированным высвобождением ницерголина
JP2008540405A5 (enExample)
JP2020506169A5 (enExample)